1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsBreast Cancer Research Grants is sponsored by PA Breast Cancer Coalition. The PA Breast Cancer Coalition (PBCC) is accepting applications for breast cancer research grants. Each year, the PBCC awards grants to Pennsylvania scientists focused on finding breakthroughs in the detection and treatment of breast cancer.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
PBCC Research Grants - PA Breast Cancer Coalition To date, the PA Breast Cancer Coalition has awarded more than $6. 6 million to Pennsylvania breast cancer researchers, bringing us one step closer to “finding a cure now… so our daughter don’t have to. ” Apply now for a 2027 PA Breast Cancer Coalition research grant!
The PA Breast Cancer Coalition is now accepting applications for breast cancer research grants of $100,000 each for the period of January 1, 2027 – December 31, 2027 . Each year, the PBCC awards grants to Pennsylvania scientists focused on finding breakthroughs in the detection and treatment of breast cancer.
opens in a new window Download the 2027 research grant application opens in a new window Download the budget Interested in serving on our Research Grants Review Committee? Click here. Congratulations, 2026 PBCC Research Grant Awardees!
This study investigates how dormant breast cancer cells survive treatment and later return as therapy-resistant metastatic tumors. The team discovered that the protein SEPP1 plays a key role in helping these cells survive and driving tumor recurrence. Patients whose tumors gain extra copies of the SEPP1 gene tend to have poorer outcomes.
Experiments show that targeting SEPP1 can eliminate dormant cancer cells and prevent tumor recurrence in mice. Understanding the role of SEPP1 provides a promising path to develop new therapies aimed at stopping metastatic breast cancer and improving patient survival. Learn more about Dr. Chodosh’s research This study aims to use a novel imaging technique, DNP-13C-MRSI, to detect and measure dormant breast cancer cells.
Researchers will also test whether this method can predict tumor recurrence after therapy. The findings will guide early clinical trials in patients with invasive breast cancer, exploring its potential to forecast treatment response, recurrence risk, and long-term outcomes.
This work represents the first use of hyperpolarized MRI to study breast cancer dormancy and could become a powerful tool for improving prognosis and personalizing therapy to reduce the risk of cancer returning. Learn more about Dr. Edmonds’s research Thomas Jefferson University This research focuses on understanding why some triple-negative breast cancer (TNBC) cells resist new targeted treatments.
TNBC is an aggressive cancer with high relapse rates, frequent metastasis, and poor survival, often driven by mutations in the p53 gene that make tumor cells more aggressive. The team discovered that p53-mutated TNBC cells rely on a protein called MDM2 to survive. A new compound has been developed to destroy MDM2 and kill these cancer cells.
This study aims to uncover how TNBC cells might develop resistance to this treatment, ultimately guiding more effective therapies for patients. Learn more about Dr. Eischen’s research This research focuses on developing more precise breast cancer treatments by targeting mechanisms that drive tumor growth and spread. The studies investigate dielectric barrier discharge plasma (DBDP), a form of non-thermal plasma, as a potential therapy.
DBDP can activate immune responses against both treated tumors and untreated metastatic tumors, making it a patient-specific immunotherapy. The research explores how DBDP triggers tumor-specific immune responses and how it can be combined with other therapies for greater effectiveness. These studies aim to establish proof of concept for DBDP and lay the foundation for new breast cancer treatments.
Learn more about Dr. Krebs’s research Thomas Jefferson University This research focuses on improving immunotherapy for breast cancer, which often fails because tumors block immune cells from accessing the nutrients they need to fight cancer. Breast tumors consume the nutrient acetate, depriving immune cells. A drug has been developed that blocks tumors from using acetate while leaving it available for immune cells.
In preclinical studies, this approach activates immune cells to target tumors and is effective across multiple breast cancer subtypes. These findings could lead to more effective, less toxic treatments and support clinical trials combining acetate metabolism inhibitors with immune cell therapies like CAR-T. Learn more about Dr. Schug’s reserach The PA Breast Cancer Coalition awards $500,000 in Research Grants in 2026.
To date, the program has awarded more than $6. 6 million to outstanding Pennsylvania scientists. Because of your support, we are able to help Pennsylvania breast cancer researchers get their innovative ideas off the ground.
Make a gift to the future of breast cancer treatment today. opens in a new window Donate Now PBCC Research Grant Reviewers Wanted Help us select future PA Breast Cancer Coalition Research Grant winners! Give today to empower survivors, advance research, and strengthen communities battling breast cancer.
Your gift today brings us closer to a future free of breast cancer—thank you for making an impact.
According to the current listing, eligibility includes: Pennsylvania scientists focused on breast cancer research. Universities are eligible. Confirm the full requirements in the official notice before applying.
The current listing shows $100,000. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for Breast Cancer Research Grants are due March 1, 2027. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Breast Cancer Research Grants is funded by PA Breast Cancer Coalition. Verify program details on the funder's official page before applying.
This opportunity targets applicants in Pennsylvania. If your organization operates elsewhere, check the official notice for location requirements.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
CDMRP reissued the FY26 BCRP Breakthrough Award Levels 1 and 2 and the Clinical Research Extension Award on September 3, 2026, with a November 4 pre-application deadline and a November 18 full application deadline. Round one closed July 8. The arithmetic across both windows accounts for nearly the entire FY26 appropriation — which tells you what kind of second chance this is.
Read articleThe OpenAI Foundation is putting $100 million behind Breakthroughs to Follow-Through, a Common Health Coalition initiative aiming to at least double hepatitis C cure rates in eight states and localities within two years. Alabama, Illinois, Louisiana and Massachusetts go first, money flows to local collaboratives and nonprofits, and the grants are deliberately not tied to any one AI vendor. Here is what makes an organization fundable under it.
Read articleThe Bureau of Democracy, Human Rights, and Labor has opened NOFO DFOP0019327, a $2.96 million single-award competition to build a global coalition countering transnational repression — the practice of governments reaching across borders to silence dissidents, journalists, and diaspora communities. Applications from nonprofits, think tanks, and NGOs are due August 12, 2026. Here is what transnational repression is, what DRL is actually buying, who is eligible, and how to build a competitive proposal for a winner-take-all award.
Read article